Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical, has received acceptance for the marketing authorization application of Roflumilast cream (ZORYVE®) 0.05%, aimed at treating mild to moderate atopic dermatitis in children aged 2 to 5, marking a significant milestone in the product's development and enhancing the company's competitive edge in autoimmune skin treatments [1][2]. Group 1: Product Development and Market Position - The active ingredient of ZORYVE® is Roflumilast, a highly selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by inhibiting the production of pro-inflammatory mediators [1]. - The cream is part of a collaboration with Arcutis Biotherapeutics, Inc., granting Huadong Medicine exclusive rights for development, registration, production, and commercialization in Greater China and Southeast Asia [1]. - The application targets a significant unmet need in the market, particularly for children aged 2 to 5, where treatment options are currently limited to traditional topical corticosteroids and calcineurin inhibitors [2]. Group 2: Market Demand and Clinical Need - There are approximately 67 million atopic dermatitis patients in China, indicating a substantial unmet clinical demand [2]. - The prevalence of atopic dermatitis in children aged 1 to 7 is reported at 12.94%, highlighting the urgent need for safe and effective treatment options for this age group [2]. - The acceptance of the 0.05% cream application is expected to provide new treatment options for pediatric patients, establishing a differentiated market barrier and first-mover advantage for Huadong Medicine in a competitive landscape [2]. Group 3: Broader Product Portfolio - Huadong Medicine has developed a differentiated product pipeline that includes various concentrations of Roflumilast cream, with higher concentrations (0.15% and 0.3%) also having received regulatory acceptance for treating older patients with atopic dermatitis and psoriasis [3]. - Additionally, a foam formulation of Roflumilast (ZORYVE®) 0.3% for seborrheic dermatitis in patients aged 9 and above is currently undergoing Phase III clinical trials [3].

智通财经APP讯，华东医药(000963.SZ)公告，公司全资子公司杭州中美华东制药有限公司(简称"中美华 东")收到国家药品监督管理局(NMPA)签发的《受理通知书》，罗氟司特乳膏(ZORYVE®)0.05%上市许 可申请获得受理，申报适应症为：适用于2岁至5岁轻度至中度特应性皮炎患者的局部外用治疗。 ...

Core Viewpoint - Huadong Medicine's subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical Co., has received acceptance for the marketing authorization application of Roflumilast cream (ZORYVE®) 0.05%, aimed at treating mild to moderate atopic dermatitis in children aged 2 to 5, marking a significant milestone in the product's development and enhancing the company's competitive edge in the autoimmune skin treatment sector [1][2]. Product Advantages - ZORYVE® contains Roflumilast, a highly selective non-steroidal phosphodiesterase-4 (PDE4) inhibitor that reduces inflammation by inhibiting the enzyme that increases pro-inflammatory mediators [2]. - The product was developed in collaboration with Arcutis Biotherapeutics, granting Huadong exclusive rights for development, registration, production, and commercialization in Greater China and Southeast Asia [2]. - Atopic dermatitis is a prevalent chronic inflammatory skin condition affecting both children and adults, with significant impacts on quality of life [2]. Market Demand - There are approximately 67 million atopic dermatitis patients in China, indicating a substantial unmet clinical need, particularly for children aged 1 to 7, with a prevalence rate of 12.94% [3]. - The introduction of Roflumilast cream addresses a clear gap in treatment options for children aged 2 to 5, who currently rely on traditional topical corticosteroids and calcineurin inhibitors [3]. - The cream's once-daily dosing regimen enhances treatment adherence, making it a more suitable option for young patients [3]. Strategic Development - Huadong Medicine is systematically introducing a range of Roflumilast products, including higher concentrations for older patients and other skin conditions, to establish a comprehensive presence in the autoimmune skin disease market [4]. - The company is focusing on a dual strategy of "introducing partnerships" and "independent innovation" to build a competitive product pipeline in autoimmune diseases, covering various conditions such as psoriasis and rheumatoid arthritis [5]. - Ongoing collaborations and clinical trials for other products further demonstrate the company's commitment to expanding its portfolio in the autoimmune sector [6]. Strategic Partnerships - In early 2026, Huadong Medicine deepened its strategic partnership with Denmark's MC2 Therapeutics to commercialize the Biomee® series in Greater China, enhancing its position in the topical skin treatment market [7]. - The acceptance of the Roflumilast cream application signifies the company's innovative capabilities and marks a phase of growth in the autoimmune skin disease field [7]. - With multiple differentiated product pipelines, Huadong Medicine aims to strengthen its influence in the multi-billion-dollar autoimmune market in China [7].

每经AI快讯，2月3日，华东医药（000963）(000963.SZ)公告称，全资子公司中美华东收到国家药品监 督管理局签发的《受理通知书》，罗氟司特乳膏(ZORYVE)0.05%上市许可申请获得受理，申报适应症 为适用于2岁至5岁轻度至中度特应性皮炎患者的局部外用治疗。该药物是中美华东与美国Arcutis Biotherapeutics,Inc.合作引进的创新皮肤外用制剂产品，中美华东拥有在大中华区及东南亚的独家权 益。罗氟司特乳膏0.05%相比传统治疗手段有安全性优势，且可用于所有部位，每日一次给药，提高治 疗依从性。该产品研发进程中的重要里程碑，将提升公司在自免皮肤治疗领域的核心竞争力。但药品审 评审批时间、审批结果及未来市场竞争形势存在不确定性。 ...

英派药业以自主创新为核心驱动力，凭借塞纳帕利的临床突破与商业化成功，不仅为卵巢癌治疗领域树 立了新标杆，更彰显了中国创新药企在全球精准抗癌赛道的竞争力。未来，随着全球临床与商业化布局 的持续深化，英派药业将继续依托合成致死技术平台，推动更多创新疗法落地，为全球癌症患者带来更 优质、更可及的治疗选择，助力生物医药产业高质量发展。 作为致死率最高的妇科肿瘤之一，卵巢癌因高侵袭性和复杂分子特征，长期困扰着全球医疗领域。约 50%的卵巢癌患者存在同源重组缺陷(HRD)，而70%-80%的患者为BRCA野生型，这部分群体此前缺乏 普适性的高效治疗方案。南京英派药业股份有限公司自2009年成立以来，始终聚焦合成致死机制的精准 抗癌疗法，已成为全球仅有的三家同时拥有商业化阶段PARP1/2抑制剂和临床阶段新一代PARP1选择性 抑制剂的公司之一。其核心产品塞纳帕利(新型PARP1/2抑制剂)凭借独特的分子设计，实现了高活性、 高选择性与广泛安全窗口的平衡，是其应用于更广泛的卵巢癌患者群体的基础。 在临床研发阶段，塞纳帕利的III期注册性研究(FLAMES研究)结果已发表于国际顶级医学期刊《Nature Medicine》。 ...

Core Viewpoint - The domestic AI-assisted medical technology is advancing, with significant developments in the approval of innovative medical devices and the application of AI in healthcare, indicating a potential for rapid growth in the AI+ healthcare market [1][2]. Group 1: Market Performance - As of February 3, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.57%, with notable gains from stocks such as Aimeike (+4.07%), Jianfan Bio (+2.36%), and Xinhengcheng (+2.29%) [1]. - The Medical Innovation ETF (516820) also rose by 0.57%, with the latest price reported at 0.36 yuan [1]. Group 2: AI in Healthcare - AI applications in smart healthcare are becoming mature, particularly in medical imaging diagnostics, where AI assists doctors in improving interpretation efficiency [2]. - Recent AI medical products have accelerated their market entry, including the "Cervical Cell Digital Pathology Image Auxiliary Diagnosis Software" approved in January 2026 and the "Yuan Zhi" model from United Imaging, which achieved over 95% accuracy in complex lesion diagnosis [2]. - The combination of technological iteration and policy support is expected to drive rapid growth in the domestic AI+ healthcare market [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and R&D innovation capabilities, reflecting the overall performance of profitable and growth-oriented medical and medical device companies [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Hengrui Medicine, collectively accounting for 63.9% of the index [2].

Group 1 - The core viewpoint of the news highlights the positive performance of the medical innovation sector, with the CSI Medical and Medical Device Innovation Index showing mixed results among its constituent stocks, led by Aimeike with a 2.18% increase [1] - The Medical Innovation ETF has seen continuous net inflows over the past 12 days, with a peak single-day net inflow of 41.83 million yuan, totaling 234 million yuan, averaging 19.54 million yuan per day [1] - Policy support for the pharmaceutical industry is ongoing, with Shanghai accelerating the implementation of major industrial projects in fields such as integrated circuits, biomedicine, and artificial intelligence [1] Group 2 - The CSI Medical and Medical Device Innovation Index consists of 30 listed companies with good profitability, growth potential, and research innovation capabilities, reflecting the overall performance of profitable and growth-oriented pharmaceutical and medical device companies [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, accounting for 63.9% of the total index weight [2] - The success rate of Phase I clinical trials for dozens of AI-derived pipelines entering trials in 2025 is projected to be as high as 80%-90%, significantly exceeding traditional levels of 40%-65% [1]

Core Viewpoint - The report highlights the growth trends in China's chemical pharmaceutical raw material production, indicating a steady increase in output and providing insights into future market dynamics [1] Industry Summary - As of December 2025, China's chemical pharmaceutical raw material production reached 361,000 tons, reflecting a year-on-year growth of 2.3% [1] - The cumulative production of chemical pharmaceutical raw materials for the entire year of 2025 was 3,707,000 tons, showing a cumulative growth of 1.6% [1] - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry research institution in China [1] Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1] - The report provides a comprehensive analysis of the market supply and demand situation in the chemical pharmaceutical industry from 2026 to 2032, offering insights for investment decisions [1]

（文章来源：证券日报） 证券日报网讯 2月2日，华东医药在互动平台回答投资者提问时表示，公司与苏州时安生物技术有限公 司合作的针对创新减重机制的siRNA创新疗法，目前已完成临床前候选化合物（PCC）确认，公司目前 拥有该产品在合作领域内（指适用于所有人类疾病的治疗、缓解或预防领域）的全球权益。 ...

消息面上，2月1日，华为云正式宣布，"行业AI梦工厂"首个落地成果——智慧医疗专区亮相，同时，即 日起启动公开测试，率先开放健康管理与病理AI辅助诊断两大核心功能，面向广大医疗机构、医生及 大众开放服务与体验。该专区深度融合上海瑞金医院等顶尖医疗机构的临床经验与华为在云、AI及ICT 领域的技术积累，旨在构建一个端到端的AI赋能平台。 光大证券强调，在医保控费（DRG/DIP）与大模型技术奇点双重驱动下，AI已成为医疗新基建的核心 生产力；其中AI制药因能显著缩短研发周期、药企付费意愿最强，AI医学影像是当前落地最成熟的赛 道，而AI慢病管理和AI手术机器人则分别依托商业保险降本逻辑与医疗资源均衡逻辑，具备强国产化 替代潜力。未来竞争核心在于独家高质量私有数据与业务场景闭环能力。 医疗创新ETF紧密跟踪中证医药及医疗器械创新指数，中证医药及医疗器械创新指数从医药卫生行业的 上市公司中，选取30只盈利能力较好且具备一定成长性和研发创新能力的上市公司证券作为指数样本， 以反映兼具盈利性与成长性的医药及医疗器械上市公司证券的整体表现。 截至2026年2月2日 10:44，中证医药及医疗器械创新指数(931484)下 ...